Neighborhood Socioeconomic Disadvantage and Hospitalized Heart Failure Outcomes in the American Heart Association Get With The Guidelines-Heart Failure Registry.


Journal

Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941

Informations de publication

Date de publication:
11 2022
Historique:
entrez: 15 11 2022
pubmed: 16 11 2022
medline: 19 11 2022
Statut: ppublish

Résumé

Neighborhood socioeconomic status (SES) is associated with worse health outcomes, yet its relationship with in-hospital heart failure (HF) outcomes and quality metrics are underexplored. We examined the association between socioeconomic neighborhood disadvantage and in-hospital HF outcomes for patients from diverse neighborhoods in the Get With The Guidelines-Heart Failure registry. SES-disadvantage scores were derived from geocoded US census data using a validated algorithm, which incorporated household income, home value, rent, education, and employment. We examined the association between SES-disadvantage quintiles with all-cause in-hospital mortality, adjusting for demographics and comorbidities. Of 593 053 patients hospitalized for HF between 2017 and 2020, 321 314 (54%) had residential ZIP Codes recorded. Patients from the most compared with least disadvantaged neighborhoods were younger (mean age 67 versus 76 years), more often Black (42% versus 9%) or Hispanic (14% versus 5%), and had higher comorbidity burden. Demographic-adjusted length of stay increased by ≈1.5 hours with each increment in worsening SES-disadvantage quintiles. Adjusted-mortality odds ratios increased with worsening SES-disadvantage quintiles ( Patients hospitalized for HF from disadvantaged neighborhoods were younger and more often Black or Hispanic. SES disadvantage was independently associated with higher in-hospital mortality. Further research is needed to characterize care delivery patterns in disadvantaged neighborhoods and to address social determinants of health among patients hospitalized for HF. gov; Unique identifier: NCT02693509.

Sections du résumé

BACKGROUND
Neighborhood socioeconomic status (SES) is associated with worse health outcomes, yet its relationship with in-hospital heart failure (HF) outcomes and quality metrics are underexplored. We examined the association between socioeconomic neighborhood disadvantage and in-hospital HF outcomes for patients from diverse neighborhoods in the Get With The Guidelines-Heart Failure registry.
METHODS
SES-disadvantage scores were derived from geocoded US census data using a validated algorithm, which incorporated household income, home value, rent, education, and employment. We examined the association between SES-disadvantage quintiles with all-cause in-hospital mortality, adjusting for demographics and comorbidities.
RESULTS
Of 593 053 patients hospitalized for HF between 2017 and 2020, 321 314 (54%) had residential ZIP Codes recorded. Patients from the most compared with least disadvantaged neighborhoods were younger (mean age 67 versus 76 years), more often Black (42% versus 9%) or Hispanic (14% versus 5%), and had higher comorbidity burden. Demographic-adjusted length of stay increased by ≈1.5 hours with each increment in worsening SES-disadvantage quintiles. Adjusted-mortality odds ratios increased with worsening SES-disadvantage quintiles (
CONCLUSIONS
Patients hospitalized for HF from disadvantaged neighborhoods were younger and more often Black or Hispanic. SES disadvantage was independently associated with higher in-hospital mortality. Further research is needed to characterize care delivery patterns in disadvantaged neighborhoods and to address social determinants of health among patients hospitalized for HF.
CLINICALTRIALS
gov; Unique identifier: NCT02693509.

Identifiants

pubmed: 36378758
doi: 10.1161/CIRCHEARTFAILURE.121.009353
pmc: PMC9673180
mid: NIHMS1823997
doi:

Banques de données

ClinicalTrials.gov
['NCT02693509']

Types de publication

Clinical Study Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e009353

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL151744
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL069749
Pays : United States

Références

Circ Cardiovasc Qual Outcomes. 2018 Jun;11(6):e004054
pubmed: 29848476
Prev Chronic Dis. 2016 Sep 01;13:E119
pubmed: 27584875
JAMA Surg. 2014 May;149(5):475-81
pubmed: 24623106
Circulation. 2014 Sep 16;130(12):966-75
pubmed: 25135276
JAMA. 2021 Jul 27;326(4):314-323
pubmed: 34313687
PLoS One. 2019 Jun 17;14(6):e0218462
pubmed: 31206556
J Card Fail. 2006 Dec;12(9):684-8
pubmed: 17174228
JACC Heart Fail. 2021 May;9(5):374-382
pubmed: 33839075
Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):749-56
pubmed: 25074375
JACC Heart Fail. 2020 Nov;8(11):943-953
pubmed: 32800512
J Am Coll Cardiol. 2021 Nov 16;78(20):2004-2012
pubmed: 34763778
Eur J Heart Fail. 2016 Mar;18(3):306-13
pubmed: 26467269
N Engl J Med. 2001 Jul 12;345(2):99-106
pubmed: 11450679
J Am Coll Cardiol. 2019 Mar 5;73(8):935-944
pubmed: 30819362
Sci Rep. 2020 Aug 11;10(1):13538
pubmed: 32782346
JACC Heart Fail. 2021 May;9(5):383-385
pubmed: 33839077
J Card Fail. 2021 Aug;27(8):826-836
pubmed: 34364659
Circ Heart Fail. 2021 Dec;14(12):e008403
pubmed: 34702047
Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32
pubmed: 20123668
Eur J Heart Fail. 2022 Jun;24(6):1117-1128
pubmed: 35289038
J Neurosurg. 2015 Mar;122(3):595-601
pubmed: 25415069
Am Heart J. 2004 Nov;148(5 Suppl):S46-8
pubmed: 15514634
Nat Rev Cardiol. 2015 Apr;12(4):220-9
pubmed: 25666406
J Am Coll Surg. 2011 Dec;213(6):699-708
pubmed: 21958511
Circulation. 2021 Oct 19;144(16):1272-1279
pubmed: 34662161
Am J Prev Med. 2018 Nov;55(5 Suppl 1):S31-S39
pubmed: 30670199
J Card Fail. 2022 May;28(5):697-709
pubmed: 34628014
JAMA Intern Med. 2015 Jun;175(6):996-1004
pubmed: 25895156
Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):389-98
pubmed: 21693723
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
N Engl J Med. 2021 Jan 14;384(2):117-128
pubmed: 33200892
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
J Am Coll Cardiol. 2018 Jun 12;71(23):2643-2652
pubmed: 29880124
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
Ethn Dis. 2007 Spring;17(2):206-13
pubmed: 17682347
Crit Pathw Cardiol. 2006 Dec;5(4):179-86
pubmed: 18340235

Auteurs

Vishal N Rao (VN)

Division of Cardiology, Duke University Medical Center, Durham, NC (V.N.R., R.J.M., A.C.C., M.D.K., M.F., A.D.D.).
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (V.N.R., R.J.M., M.D.K., M.F., R.A.M., A.D.D.).

Robert J Mentz (RJ)

Division of Cardiology, Duke University Medical Center, Durham, NC (V.N.R., R.J.M., A.C.C., M.D.K., M.F., A.D.D.).
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (V.N.R., R.J.M., M.D.K., M.F., R.A.M., A.D.D.).

Amanda C Coniglio (AC)

Division of Cardiology, Duke University Medical Center, Durham, NC (V.N.R., R.J.M., A.C.C., M.D.K., M.F., A.D.D.).

Michelle D Kelsey (MD)

Division of Cardiology, Duke University Medical Center, Durham, NC (V.N.R., R.J.M., A.C.C., M.D.K., M.F., A.D.D.).
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (V.N.R., R.J.M., M.D.K., M.F., R.A.M., A.D.D.).

Marat Fudim (M)

Division of Cardiology, Duke University Medical Center, Durham, NC (V.N.R., R.J.M., A.C.C., M.D.K., M.F., A.D.D.).
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (V.N.R., R.J.M., M.D.K., M.F., R.A.M., A.D.D.).

Gregg C Fonarow (GC)

Division of Cardiology, Department of Medicine, University of California at Los Angeles (G.C.F.).

Roland A Matsouaka (RA)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (V.N.R., R.J.M., M.D.K., M.F., R.A.M., A.D.D.).

Adam D DeVore (AD)

Division of Cardiology, Duke University Medical Center, Durham, NC (V.N.R., R.J.M., A.C.C., M.D.K., M.F., A.D.D.).
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (V.N.R., R.J.M., M.D.K., M.F., R.A.M., A.D.D.).

Melissa C Caughey (MC)

Joint Department of Biomedical Engineering, University of North Carolina and North Carolina State University, Chapel Hill (M.C.C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH